Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies
To the Editor:
We read with interest the results published by Socinski et al. who compared arm B (atezolizumab, bevacizumab, and chemotherapy) and arm C (bevacizumab and chemotherapy) from the IMPower 150 trial. Adding a checkpoint inhibitor (CI) improves significantly overall survival, progression-free survival, and overall response rate at the price of greater toxicities. 1 Nevertheless, it could become a new standard of care in the future.
In the area of precision medicine, we emphasize the importance of identifying which drug is responsible for toxicity in order not to stop potentially efficient therapies.
To illustrate this issue, we report the case of a patient treated with a combination of antiangiogenics and CI who developed unusual acute kidney injury (AKI). Renal toxicities can occur with both agents. Vascular endothelial growth factor (VEGF) pathway inhibitors may induce proteinuria and increased blood pressure, mainly caused by thrombotic microangiopathy (TMA) localized to the kidney, whereas CI may induce acute interstitial nephritis (AIN) leading to AKI. Treatment should include angiotensin-converting enzyme inhibitors and suspension of VEGF inhibitors for TMA. Immune-related AIN is most often reversible with the suspension of CI and corticosteroids treatment. 2, 3 A 63-year-old male with stage IV (lung and brain metastases) lung adenocarcinoma without oncogenic driver developed moderate renal impairment after first-line chemotherapy with cisplatin and pemetrexed leading to treatment discontinuation. Four months later, computed tomographic scan revealed disease progression.
He was enrolled in a phase I trial evaluating ramucirumab (anti-VEGF-receptor 2) and MEDI4736 (antiprogrammed death ligand 1). The first dose was administered in July 2016. Creatinine was 168 mmol/L.
He had no serious adverse event for 15 months except grade 2 high blood pressure without proteinuria treated with ramipril 2.5 mg. Creatinine levels remained stable. A computed tomographic scan revealed a partial response. In October 2017, he experienced persistent grade 2 increased creatinine levels (239 mmol/L) despite rehydration. Renal ultrasonography did not reveal urinary tract dilatation. Proteinuria was 0.3 g/g. Blood pressure was well controlled. No hematuria, leukocyturia, or edema was present.
A nephrologist's opinion was required through the "Oncosafety" network, which is a network of specialists created at the Assistance Publique Hôpitaux de Marseille, France, which oversees the management of anticancer therapeutics toxicities.
In absence of biological markers of TMA or AIN, a renal biopsy was indicated. Optical microscopy suggested TMA induced by the VEGF receptor inhibitor. Ramucirumab was stopped, and anti-programmed death ligand 1 treatment continued. The ramipril dose was increased to 5 mg. After 9 months of follow-up, creatinine level stabilized to around 200 mmol/L and the patient is still responding to treatment.
The main renal complication reported with ramucirumab is proteinuria, occurring in 5.8% to 17%. 4 AKI is not described as a frequent adverse event. Physicians must be aware of unusual presentation, as in this case, nephrotoxicity of ramucirumab without proteinuria. Renal biopsy appears to be useful and should be quickly considered to guide treatment and limit toxicity.
More generally, close collaboration between oncologists and specialists in a dedicated network is necessary for the management of toxicities associated with anticancer therapies.
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
To the Editor: Treatment of EGFR-mutated lung adenocarcinoma is based on EGFR tyrosine kinase inhibitors (TKIs). MNNG HOS Transforming gene (MET ) amplification has been described as a resistance mechanism to EGFR TKIs. Only a few reports have been made concerning the treatment of acquired MET amplification in EGFR-mutated adenocarcinoma. [1] [2] [3] [4] We here report the outcomes of two patients treated with an association of EGFR-TKI and crizotinib for EGFR-mutated adenocarcinoma with acquired MET amplification.
The first patient was 68-year-old woman diagnosed with an advanced lung adenocarcinoma. An EGFR mutation (deletion in the exon 19) was found, and the patient received afatinib. Progression occurred 9 months later in the right lower limb (bone and muscular metastases). A biopsy of a muscular metastasis revealed adenocarcinoma with mutation in the EGFR exon 19, no T790M mutation, and MET amplification. The patient was then treated with carboplatinþpaclitaxel, with an early tumor progression (brain and right lower limb). A biopsy was performed on a progressive metastasis showing the same molecular profile. The patient was then treated with erlotinib (150 mg per day) and crizotinib (500 mg per day). At 2 months, a tumor response (limb and brain) was observed (Fig. 1) . Unfortunately, a progression occurred after 4 months of treatment (liver and right lower limb). A new biopsy showed the presence of the exon 19 deletion with no T790M and the persistence of the MET amplification. The patient underwent then chemotherapy.
The second patient was a 59-year-old women diagnosed with a right upper lobe lung adenocarcinoma who was treated by lobectomy. Pathology results showed a distant pleural metastasis and an EGFR mutation (L858R). The patient received a treatment by gefitinib during 18 months after surgery. Progression occurred 6 months later with one brain metastasis and a mediastinal lymphadenopathy. The patient received mediastinal radiochemotherapy and brain stereotactic radiotherapy. Because of tumor progressions, the patient received carboplatin-pemetrexed, erlotinib, and then docetaxel, successively. Later, a biopsy on a progressive metastasis showed a T790M mutation. A treatment by osimertinib was started, resulting in tumor response. After 15 months, progression occurred on thorax and bone. A new biopsy was performed showing the L858R mutation, the T790M mutation, and an MET amplification. The patient received crizotinib (500 mg per day) and osimertinib (80 mg per day). One month after treatment a tumor response was observed (Fig. 2) . The patient died 2 months later from a pulmonary infection without disease progression.
MET amplification has been described as a resistance mechanism in 5% to 20% of patients treated with firstor second-generation TKIs. This proportion seems higher with osimertinib (up to 30%). Recent reports have shown a poor efficacy of crizotinib given as monotherapy for MET amplified NSCLC. 5 Only a few case reports have been published describing the efficacy of the combination of crizotinib and EGFR TKIs, and only one with osimertinib. [1] [2] [3] [4] We report here cases showing tumor response with this treatment strategy, even if progression occurred quickly in one patient. Prospective clinical trials are needed to address this issue.
